Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29097411 | 1.00 | HSD17B10 (0.39) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL22412830 | 1.00 | HSD17B10 (0.39) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL31607100 | 1.00 | HSD17B10 (0.39) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL30616573 | 1.00 | HSD17B10 (0.39) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL30616555 | 1.00 | HSD17B10 (0.39) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL27319966 | 0.82 | NR1H2 (0.42) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL21227876 | 0.82 | NR1H2 (0.42) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL19614281 | 0.82 | HSD17B10 (0.43) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15720196 | 0.82 | HSD17B10 (0.43) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL31075917 | 0.82 | HSD17B10 (0.43) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139299-B1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4139299-A1 | KRAS G12D PROTEIN INHIBITORS | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 3869/4885NR1H2 3358/4885CHRM2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.